Caption Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Caption Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.9M	Buy	220,000 +200,000	+1,000%	+$4.78M	0.03%	539
2025 Q4	$534K	Sell	20,000 -156,300	-89%	-$3.74M	﹤0.01%	1231
2025 Q3	$3.76M	Buy	176,300 +146,300	+488%	+$3.46M	0.03%	594
2025 Q2	$647K	Buy	30,000 +10,000	+50%	+$186K	0.01%	1051
2025 Q1	$332K	Buy	+20,000	New	+$363K	﹤0.01%	1181
2024 Q4	–	Sell	-60,000	Closed	-$923K	–	1422
2024 Q3	$923K	Buy	60,000 +30,000	+100%	+$500K	0.01%	803
2024 Q2	$488K	Sell	30,000 -153,400	-84%	-$2.48M	0.01%	815
2024 Q1	$3.39M	Buy	+183,400	New	+$4.54M	0.05%	397
2023 Q4	–	Sell	-72,500	Closed	-$1.51M	–	1294
2023 Q3	$1.51M	Buy	72,500 +45,000	+164%	+$1.22M	0.02%	652
2023 Q2	$659K	Buy	+27,500	New	+$611K	0.01%	759
2022 Q4	–	Sell	-45,000	Closed	-$738K	–	1234
2022 Q3	$738K	Sell	45,000 -20,000	-31%	-$324K	0.01%	969
2022 Q2	$916K	Sell	65,000 -18,700	-22%	-$349K	0.01%	906
2022 Q1	$2.03M	Sell	83,700 -35,000	-29%	-$847K	0.02%	751
2021 Q4	$2.77M	Buy	+118,700	New	+$2.39M	0.03%	670
2021 Q2	–	Sell	-251,000	Closed	-$6.47M	–	1251
2021 Q1	$6.47M	Buy	251,000 +165,800	+195%	+$7.3M	0.14%	186
2020 Q4	$4.56M	Buy	85,200 +30,000	+54%	+$1.49M	0.1%	248
2020 Q3	$2.28M	Hold	55,200	–	–	0.05%	393
2020 Q2	$2.67M	Buy	+55,200	New	+$2.65M	0.09%	308
2020 Q1	–	Sell	-80,000	Closed	-$3.42M	–	825
2019 Q4	$3.42M	Buy	80,000 +20,000	+33%	+$870K	0.12%	247
2019 Q3	$2.16M	Sell	60,000 -67,900	-53%	-$2.06M	0.11%	224
2019 Q2	$3.42M	Buy	127,900 +92,900	+265%	+$2.37M	0.17%	170
2019 Q1	$940K	Buy	+35,000	New	+$817K	0.05%	366

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Caption Management's ACAD Position: Q1 2026 in Review

Caption Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 120,877 shares worth $2.69M. The stake represents 0.02% of the portfolio and ranks #738 among its holdings. This is a return to the name: Caption Management previously reported a position in ACAD as recently as Q2 2025.

Caption Management first reported a position in ACAD in Q2 2018 and has held it in 16 quarters since. The position peaked at $3.24M in Q4 2020. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Caption Management held 120,877 shares of Acadia Pharmaceuticals worth $2.69M as of Q1 2026.
Acadia Pharmaceuticals was a new Caption Management position in Q1 2026.
Acadia Pharmaceuticals made up 0.02% of Caption Management's portfolio in Q1 2026, its #738 holding.
Caption Management first reported a position in Acadia Pharmaceuticals in Q2 2018 and has held it in 16 quarters since.
Caption Management's Acadia Pharmaceuticals position peaked at $3.24M in Q4 2020.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.